{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-283698","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.962637+00:00","generated_at":"2026-06-21T20:02:29.382867+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantheus enters two license/collaboration deals with POINT for up to $1.87B in milestones, $260M upfront","bullets":["Upfront cash: $250M for PNT-2002 (PSMA therapy) and $10M for PNT-2003 (SSTR therapy); combined potential milestones ~$1.87B.","PNT-2002 targets PSMA for metastatic castrate-resistant prostate cancer; POINT responsible for clinical development.","PNT-2003 targets SSTR-positive neuroendocrine tumors; Lantheus leads regulatory filings and commercialization post-approval.","Royalties: 20% PNT-2002 net sales after $500M cumulative gross profit; 15% PNT-2003 net sales.","Closing subject to HSR review; outside date June 30, 2023 (extendable by Lantheus to Aug 30, 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-283698","json":"https://secwatch.observer/filing/0001193125-22-283698.json","markdown":"https://secwatch.observer/filing/0001193125-22-283698.md","text":"https://secwatch.observer/filing/0001193125-22-283698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/0001193125-22-283698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/d378760d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:02:29.382867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7796f6b6feffbfd6171d02b174533ad650eef41","claim":"Lantheus Holdings, Inc. entered into PNT-2002 License Agreement with POINT Biopharma Global Inc. valued at Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, Lantheus Two, LLC (“Lantheus Two”), an indirect wholly owned subsidiary of Lantheus Holdings, Inc. (the “Company”), entered into a license and collaboration agreement (the “PNT-2002 License Agreement”) with an affiliate of POINT Biopharma Global Inc. (“POINT”), to co-develop and commercialize PNT-2002, a prostate-specific membrane antigen-targeted radiopharmaceutical therapy for the treatment of metastatic castrate-resistant prostate cancer.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/0001193125-22-283698-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"POINT Biopharma Global Inc."},{"label":"Value","value":"Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto"},{"label":"Effective","value":"2022-11-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}